Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in NSCLC
Research type
Research Study
Full title
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)
IRAS ID
1006309
Contact name
Joseph Park
Contact email
Sponsor organisation
Gilead Sciences, Inc.
Research summary
This is a clinical research study aimed at individuals that have been diagnosed with a type of cancer called metastatic non-small cell lung cancer (NSCLC) and may have or may have not received prior treatment for this disease. The purpose of this study is to is to see if different combinations of experimental drugs are safe and effective when compared to approved treatments for NSCLC. The study will be divided into 2 different sub-studies depending on whether a participant has received previous disease treatment or not. For participants that have not received previous disease treatment, the study will test different combinations of zimberelimab, domvanalimab, sacituzumab govitecan and etrumadenant, whereas for participants that have received previous disease treatment the study will test different combinations of zimberelimab, sacituzumab govitecan, etrumadenant and GS-3583. Regardless of whether participants have received previous treatment or not, participants entering this study will receive study medication as there is no placebo (a substance known to be inactive). Sacituzumab govitecan is currently approved in the United Kingdom for the treatment of certain types of breast cancer and certain types of urothelial cancer, Zimberelimab is currently approved in China by the for the treatment of classical Hodgkin lymphoma whereas etrumadenant and domvanalimab have not yet been approved for the treatment of any disease.
This research study will be conducted in a multicentre setting across different countries, where about 25 study sites will participate, including in the United Kingdom. This is an open-label study, meaning that the participant and the study doctor will know what study drugs the participant will be taking.
This research is of vital importance as Lung cancer is the leading cause of cancer-related mortality worldwide. It was estimated that in 2020 there were over 2 million new cases of lung cancer and approximately 1.8 million deaths worldwide.REC name
London - Brent Research Ethics Committee
REC reference
23/LO/0217
Date of REC Opinion
20 Sep 2023
REC opinion
Further Information Favourable Opinion